Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
about
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.Pharmacological enhancement of memory or cognition in normal subjectsCharacterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy.CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's diseaseProlonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy.Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease.Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment StrategyUse of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.Induced Pluripotent Stem Cells Derived from Alzheimer's Disease Patients: The Promise, the Hope and the Path Ahead.Benefits and risks of add-on therapies for Alzheimer's disease.Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease.Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Caregiver Preference and Treatment Compliance in Patients with Mild-to-Moderate Alzheimer's Disease in South Korea: RECAP Study Results.Pharmacokinetic and pharmacodynamic alterations in older people with dementia.Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.Memantine for the treatment of general neuropathic pain: a narrative review.A Therapeutic Insight of Niacin and Coenzyme Q10 Against Diabetic Encephalopathy in Rats.Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?The Black Book of Psychotropic Dosing and Monitoring.Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS).New 2-Aryl-9-methyl-β-carbolinium salts as Potential Acetylcholinesterase Inhibitor agents: Synthesis, Bioactivity and Structure-Activity Relationship.Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice.Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities
P2860
Q33165801-1B166CB7-AEBA-4F86-83FF-1330D8D18C44Q33586027-A3B6A479-223C-4DAA-844B-98651BD8738CQ33659760-AEE4BD98-150F-4B52-94D1-3C3141B490DEQ34982153-FB114D62-88B7-4F06-A44C-6C7CD031ACFFQ35082774-1DBF50A1-A94F-4BE7-B5FC-0380A4BC75A7Q35841781-ECF7A955-B74E-440E-82A0-043F886B1168Q36384458-871472DE-3CD6-46F2-90BC-52418162B6FAQ37553489-17705824-3DE3-40AD-8577-FE7F8F8D9546Q38181868-31D89018-57D5-41D0-AD0A-113F6D798BF7Q38559734-761A12B9-7B56-4AF5-93D8-5FAD81AA00B8Q38620338-07D1CA73-EA79-4512-BADD-52205A41B611Q38683819-50E6C0D8-93DD-4832-819A-B4C4B03E31DBQ38860423-4BFA8EC3-78AE-4693-9D66-3597F51AE302Q38959281-0E47B630-CACB-42F4-A713-AD680F10A162Q39079324-983DBF9C-1564-4644-BBC3-D4D4707180A4Q39275819-54B7A8CF-3D18-42F7-B214-4E6BCD3DCE7EQ39415447-D9A989AC-2A0C-4EC4-84D9-407F34185A6FQ43061597-5AC0ABC3-5680-43E2-960C-1CEA53EAA202Q46166368-275B76E4-823E-40F2-9414-6F4C9036FC5AQ47450129-C3C18662-7AFD-4A28-8176-3A3064BFAF77Q47642128-F91E36A3-A0C3-4B38-A05E-B761CAB7E78FQ48074095-D39877AC-DD8B-4EBE-8F85-D50A6878CD24Q49703452-3ADD01E6-61CE-4C79-83EE-8CED8DAC1FA5Q49721453-DE264EB5-B94F-470B-95F3-13A3DF5BEDA2Q51491144-D28A4106-BD36-43A4-BF15-721390ABF6BFQ52579932-007F9E2B-AE39-4438-9882-6D60FE85E0BEQ58571824-4536D15D-71CD-4E8B-8CA8-5A90FA3AC17D
P2860
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@ast
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@en
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@nl
type
label
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@ast
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@en
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@nl
prefLabel
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@ast
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@en
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@nl
P2860
P1476
Pharmacodynamic, pharmacokinet ...... atment of Alzheimer's disease.
@en
P2093
Muriel Noetzli
P2860
P2888
P304
P356
10.1007/S40262-013-0038-9
P50
P577
2013-04-01T00:00:00Z
P6179
1016362867